
é£éŠæ¿åºã®COVIDã¯ã¯ãã³è¢«å®³ããã°ã©ã ã¯æ°ããªæ»äº¡ã«å¯ŸããŠæ¯æããè¡ãããåŠèªã¯äŸç¶ãšããŠ98%ãè¶ ããŠãã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ä¿å¥è³æºäºæ¥å±ã¯6æã®æç¹ã§ãé£éŠæ¿åºã®Countermeasures Injury Compensation ProgramãéããŠ7,407ä»¶ã®è«æ±ã®ãã¡60ä»¶ã®ã¿ãè£åããŠããã7,298ä»¶ã¯è£åããŠããªããææ°ã®å ±åã«ãããšããã³ãããã¯ãå§ãŸã£ãŠä»¥æ¥ãæ»äº¡ä¿éºéãæ¯æãããã®ã¯ããã3ä»¶ç®ã§ããã
æ°ãã«çºè¡šãããé£éŠæ¿åºã®ããŒã¿ã«ãããšãCOVID-19ã¯ã¯ãã³ããã®ä»ã®å¯Ÿçã«é¢é£ããå·å®³ã®è£åãä»»åãšããæ¿åºã®ããã°ã©ã ã¯ã1ä»¶ã®æ»äº¡çµŠä»éãå«ã4ä»¶ã®è¿œå è«æ±ãæ¿èªããã
Health Resources and Services Administration(HRSA)ã¯6æã®ææ°æ å ±ã§ãCountermeasures Injury Compensation Program(CICP)ãè£å®ããã7,407ä»¶ã®è«æ±ã®ãã¡60ä»¶ãè£åãã7,298ä»¶ãæåŠãããšå ±åããã
å ±åæžã«ãããšãæåŠçã¯98%以äžã ãšããã
é£éŠæ¿åºã®ã¯ã¯ãã³è¢«å®³è£åã«é¢ãã2åã®æ¬ã®èè ã§ããç ç©¶è ã®ãŠã§ã€ã³ã»ããŒãæ°ãåŒçšããããã°ã©ã 远跡ã«ãããšãCOVID-19ã®ãã³ãããã¯ãå§ãŸã£ãŠä»¥æ¥ãæ»äº¡ã«é¢é£ããŠæ¯æãããè«æ±ã¯ãä»åã®æ°åã§3ä»¶ç®ãšãªã£ãã
6æã®æç¹ã§ããã®ããã°ã©ã ã«ã¯åèš14,152ä»¶ã®è«æ±ãå¯ããããŠããããã®ãã¡6,745ä»¶ã¯å¯©æ»åŸ ã¡ãŸãã¯å¯©æ»äžã§ããã7,407ä»¶ã«ã€ããŠã¯æ±ºå®ãäžãããŠãããHRSAã®å ±åã«ãããšã109ä»¶ã®è«æ±ãè£åã®å¯Ÿè±¡ãšã¿ãªãããŠããããç·é¡745äžãã«ã®æ¯æãã«è³ã£ãã®ã¯ããã60ä»¶ã§ããã
ã»ãšãã©ã®åŠèªã¯ãæåºæéãéããããšãå»çèšé²ãæåºããªãã£ãããšããŸãã¯è£åãããå·å®³ã«å¯Ÿããããã°ã©ã ã®èšŒæåºæºãæºãããŠããªãã£ãããšãªã©ãæç¶ãäžãŸãã¯èšŒæ äžã®çç±ã§åºãããã
ãç¡ç€Œãªã»ã©äœãå ±é ¬ã
æ³åŸå°éå®¶ãã¯ããã®ããã°ã©ã ã®æ§é ã«ãããæ¢åã®èŠåã®äžã§ã¯æ¿èªãå°é£ã«ãªã£ãŠãããšè¿°ã¹ãŠããŸãã
ã¬ã€ã»ãããŒã¬ã¹åŒè·å£«ã¯ããã«ãã¬ã³ãºã»ãã«ã¹ã»ãã£ãã§ã³ã¹(CHD)ãæ¯æŽãã蚎èšã§ãCOVID-19ã¯ã¯ãã³ã«ãã£ãŠè² å·ãã2人ã®å¥³æ§ã®ä»£ç人ãåããŠããŸãã女æ§ãã¡ã¯ãå¶éçãªæ¿çããã£ãŠãèªåãã¡ã®äž»åŒµãåŠå®ãããšããŠHRSAã蚎ããŸããã
ãHHSé·å®ã®COVID-19 PREPæ³ã«ããä¿è·ãå°ãªããšããã®10幎ã®çµãããŸã§ç¶ãéããç¡ç€Œãªã»ã©äœãæ¯æããäžè¬çã§ããç¶ããã ããããšFloresã¯è¿°ã¹ãããçŸåšãCOVID-19ã¯ã¯ãã³ã«ããæå·ã¯éããŒãã«æå·ãšããŠè£åãããŠãããããå æé¢ä¿ã蚌æãã責任ã¯ç³è«è ã«ããã
2005幎ã®å ¬è¡ç·æ¥äºæ æºåæ³(PREPæ³)ã¯ãå ¬è¡è¡çäžã®ç·æ¥äºæ ã«ãããå»ç察çã®éçºãšç®¡çã«é¢äžããè£œé æ¥è ãæµéæ¥è ãå»çæäŸè ã«å¯ŸããŠè²¬ä»»ä¿è·ãæäŸããŠããã
PREPæ³ã¯ãŸãã察象ãšãªãå¯Ÿææªçœ®ã«ãã£ãŠçŽæ¥åŒãèµ·ããããéå·ãŸãã¯æ»äº¡ã被ã£ãå人ã«å¯Ÿããé£éŠè£åã¡ã«ããºã ãšããŠCICPãèšç«ããŸããã
ãããŒã¬ã¹ã¯ãæœåšçãªCICPã®è«æ±è ãçŽé¢ãã2ã€ã®äž»èŠãªåé¡ããããšäž»åŒµãããã¯ã¯ãã³ã«ãã£ãŠè² å·ãã人ã¯ããã°ã©ã ã«ã€ããŠç¥ããªãå¯èœæ§ããããè£åãåããè³æ ŒãåŸãããã«ã¯ãè«æ±è ã¯éå·ãè² ããªããã°ãªããªãã
ãè² å·è ã®å€§åãCICPããã°ã©ã ãšãã®1幎éã®æåºæéãç¥ããªãã ãã§ãªããè² å·è ã®çŽ90%ã¯æ»äº¡ãŸãã¯éå·ãè² ã£ãŠããªããããç³è«ããè³æ ŒããªãããšãããŒã¬ã¹ã¯è¿°ã¹ãã
CICPæåŠçã¯98%以äžãç¶æ
CICPã®æåŠçã¯äžè²«ããŠé«ããŸãŸã ã
ãããŸã§ã®HRSAã®ããŒã¿ã«ãããšã4æ1æ¥æç¹ã§è£å®ããã6,944ä»¶ã®è«æ±ã®ãã¡ãè£åãããã®ã¯ããã51ä»¶ã§ã6,847ä»¶ã¯æåŠãããŠããã
é£éŠäœæ¥éšäŒãäœæããå ±åæžã¯ãä»å¹Žåãã«COVID-19ã¯ã¯ãã³ã«ããå·å®³ã®è¿œè·¡ãå€§å¹ ã«èŠçŽãããæ±ããŠããŸãã
Advisory Committee on Immunization Practicesã®COVID-19 Immunization Workgroupã®ããã«äœæãããæ©å¯èæ¡ã¯ãé£éŠä¿å¥åœå±ã«å¯ŸããŠãæ¥æ§COVID-19ã¯ã¯ãã³æ¥çš®åŸçå矀(PACVS)ãšåŒã°ãããã®ãæ£åŒã«èªèãã远跡ããããæ±ããŠããã
äžéšã®æ£è ã¯COVID-19ã¯ã¯ãã³æ¥çš®åŸã«æç¶çãªå€ç³»çµ±çç¶ãçµéšããŠããã蚺æã³ãŒããèšåºã¬ã€ãã³ã¹ããã³ãµãŒãã€ã©ã³ã¹ã·ã¹ãã ã®æ¬ åŠãéå°èªèããã³äžååãªã±ã¢ã«ã€ãªãã£ãŠããããšåå ±åã¯äž»åŒµããŠããã
ãPACVSã®èªèããã³è¿œè·¡ãã§ããŠããªãããšãæ¯æ£ãããããæ©æ¥ãªæªçœ®ãè¬ããå¿ èŠãããããšåèè ãã¯èšããäžæ¹ã§ããPACVSã«é¢ããç¥èã¯äŸç¶ãšããŠçºå±éäžã«ãããææãªç¥èæ Œå·®ãäŸç¶ãšããŠååšãããããšãèªããã
å ±åæžã¯ãACIPãPACVSå°çšã®ICD-10蚺æã³ãŒãã®äœæã蚺æãšæ²»çã®ããã®èšåºã¬ã€ãã©ã€ã³ã®éçºãPACVSãšé·æCOVIDã«çŠç¹ãåœãŠãåœéçãªç ç©¶ãšç£èŠãããã¯ãŒã¯ã®ç¢ºç«ãæ€èšããããšãæšå¥šããŠããã
ããããACIPã¯æ³çã«äžå®å®ãªç¶æ ã«ããã
ä»å¹Žåãããã©ã€ã¢ã³ã»ããŒãã£ãŒé£éŠå°è£å€äºã¯ããããŒãã»ã±ããã£Jrç±³ä¿å¥é·å®ã®äžã§æè¿è¡ãããACIPã®ä»»åœã®å€ããå·®ãæ¢ããå·®ãæ¢ãåœä»€ãåºããã
ãã®æä»€ã¯ãç±³åœå°å ç§åŠäŒ(AAP)ãã±ããã£ãšç±³åœä¿å¥çŠç¥ç(HHS)ã«å¯ŸããŠèµ·ããã蚎èšã«ç±æ¥ããŠããŸããAAPã¯ãã±ããã£ã以åã®ACIPã¡ã³ããŒãè§£éãã圌ãã亀代ãããéã«æç¶ãã«éåãããšéé£ããŸããã
ãã©ã³ãæ¿æš©ã¯å é±ããè£å€æã®åœä»€ã«ãããACIPã¯äžæ žçãªè²¬ä»»ãæããããšãã§ããªããªã£ãããšããŠãè£å€æã«äžèšŽã®è¿ éåãèŠè«ããã
ACIPã«ã³ã¡ã³ããæ±ããããåçã¯åŸãããªãã£ãã
CICPã¯æ³çãªåé¡ã«çŽé¢
COVID-19ã¯ã¯ãã³ã«å¯Ÿããé£éŠæ¿åºã®è£åå¶åºŠã¯ãæ³çãªç°è°ç³ãç«ãŠã®çŠç¹ãšãªã£ãŠããŸãã
é£éŠæ³ã¯ãã¯ã¯ãã³é¢é£ã®å·å®³ã«å¯ŸããŠ2ã€ã®äž»èŠãªè£åã·ã¹ãã ãæäŸããŠãããCICPã¯ãCOVID-19ã¯ã¯ãã³ã«ããå·å®³ããã³ã察象ãšãªã察çãã«ãããã®ä»ã®å·å®³ã察象ãšããNational Vaccine Injury Compensation Program(VICP)ã¯ãç±³åœçŸç 察çäºé²ã»ã³ã¿ãŒãæ¥åžžçã«æšå¥šããŠããå°å æã¯ã¯ãã³ãå«ãã¯ã¯ãã³ã«é¢é£ããå·å®³ã察象ãšããã
ååã®Jeanne Matereseã¯2æã«æåºããæžé¡ã§ãCOVID-19ã¯ã¯ãã³ã¯VICPã«ç§»ãããã¹ãã ã£ããšäž»åŒµããŠHHSã蚎ããããããã¯CICPã®æ çµã¿ã®äžã«ãããããè«æ±è ã¯ããçãæéãšããå°ãªãæç¶ãäžã®ä¿è·ã«çŽé¢ããã
æ¿åºã¯ãæåºæéãåããããã«è«æ±è ããã¯ã驿 Œã§ãªããªã£ãå Žåã§ããCICPã¯äŸç¶ãšããŠé©åãªä»£æ¿çææžææ®µã§ãããšäž»åŒµããŠããã®èšŽèšãåŽäžããã
VICPã¯æ¥åžžçã«æšå¥šãããã¯ã¯ãã³ã察象ãšããçŒçãèŠçãåŒè·å£«è²»çšãªã©ã®ããåºç¯ãªã«ããŽãªãŒã®æå®³è³ åãæäŸããŠããããCICPã¯ããçã驿 ŒèŠåãšããå³ããèŠä»¶ã課ããŠããã
CICPã®è«æ±è ã¯ãè² å·ãã12ã«æä»¥å ã«ç³è«ããªããã°ãªãããè£åã¯ãæãæ»ããããªãå»çè²»ã幎é50,000ãã«ãäžéãšããéãããéžå€±è³éãããã³2021幎çŸåšã®370,376ãã«ã®äžæçãªæ»äº¡çµŠä»ã«å¶éãããŠããããã®ããã°ã©ã ã¯ãçã¿ãèŠãã¿ã蚎èšè²»çšãã«ããŒããªãããŸããæ±ºå®ã¯åžæ³å¯©æ»ã®å¯Ÿè±¡ãšã¯ãªããªãã
ããŒãæ°ã¯ããã®ããã°ã©ã ã®æ çµã¿ãè«æ±è ã®æžå°ã«ã€ãªãã£ããšèããŠããŸãã
ãè«é¡ã®æåºãå€§å¹ ã«æžå°ããçç±ã¯ãè² å·è ãè£åããããã°ã©ã ã®è²§åŒ±ãªæ§é ã«é¢ãããã¥ãŒã¹ãšç¥èã®çµæã§ãããšçµè«ä»ããããšãã§ããããšåœŒã¯è¿°ã¹ããããã«ã¯çã¿ãšèŠãã¿ãå«ãŸããŠããªããšä»ãå ããã
ãããšã¯å¯Ÿç §çã«ãVICPã¯2025幎2æçŸåšã28,000件以äžã®è«é¡ãåŠçããŠããã24,602ä»¶ã®è«æ±ãè£å®ãããäžæ¹ã§ã12,931ä»¶ãäžé©æ Œãšå€æããã11,659ä»¶ã驿 Œãšã¿ãªããããã®çµæãè£åçã¯47%ãšãªã£ãã
React19ã®æ³åãã£ã¬ã¯ã¿ãŒãã¯ãªã¹ããã¡ãŒã»ããªã¹ãããæ°ã¯ãCICPã«ã¯ãç¡æ°ã®æ§é çæ¬ é¥ãããããããä»åã®æ°åã¯ãé©ãã§ã¯ãªãããšè¿°ã¹ãã
ãäœãå€ããã¹ããã¯æããã§ããããšåæ°ã¯è¿°ã¹ãããè°äŒã¯ãCOVID-19ã¯ã¯ãã³ã«ããå·å®³ãã¯ã¯ãã³å·å®³è£åããã°ã©ã ã«ç§»è¡ãããã¹ãã§ããããã®ããã°ã©ã ã§ã¯ãè«æ±è ã¯ãããé©åãªæç¶ãã«ããä¿è·ãåŒè·å£«ããã³å°éå®¶ã®å ±é ¬ã®åéãããã³ãã匷åºãªçµŠä»ã䌎ãããã確ç«ãããã·ã¹ãã ãå©çšã§ããã
ææ°ã®HSRAå ±åæžã¯ãCDCããã¡ã€ã¶ãŒç€Ÿã«å¯ŸããŠãå°å ããã³æäººã«å¯ŸããCOVID-19ã¯ã¯ãã³æ¥çš®ã®ããã®2ã€ã®é£éŠå©æéãšããŠ12å4000äžãã«ãæäžããã®ãšåãæã«çºè¡šãããŸããã
HRSAã«ã³ã¡ã³ããæ±ããããåçã¯ãªãã£ãã